A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

April 26, 2024

Study Completion Date

November 30, 2025

Conditions
CancerMelanoma
Interventions
DRUG

BMS-986253

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (72)

1011

Local Institution - 0040, Lausanne

1200

Local Institution - 0037, Brussels

2065

Local Institution - 0088, Wollstonecraft

3000

Local Institution - 0090, Melbourne

3004

Local Institution - 0095, Melbourne

5000

Local Institution - 0096, Adelaide

6009

Local Institution - 0097, Perth

8091

Local Institution - 0039, Zurich

8500

Local Institution - 0082, Kortrijk

9000

Local Institution - 0036, Ghent

9007

Local Institution - 0041, Sankt Gallen

10029

Local Institution - 0025, New York

10032

Local Institution - 0002, New York

12200

Local Institution - 0034, Berlin

13385

Local Institution - 0067, Marseille

15213

Local Institution - 0001, Pittsburgh

15706

Local Institution - 0047, Santiago de Compostela

20089

Local Institution - 0026, Rozzano-milano

20132

Local Institution - 0042, Milan

20251

Local Institution - 0053, Hamburg

21044

Local Institution - 0012, Columbia

21093

Local Institution - 0003, Lutherville

22031

Local Institution - 0015, Fairfax

23502

Local Institution - 0008, Norfolk

28034

Local Institution - 0045, Madrid

28040

Local Institution - 0022, Madrid

28050

Local Institution - 0023, Madrid

29010

Local Institution - 0044, Málaga

29615

Local Institution - 0009, Greenville

30060

Local Institution - 0101, Marietta

30322

Local Institution - 0087, Atlanta

30342

Local Institution - 0100, Atlanta

31008

Local Institution - 0021, Pamplona

31059

Local Institution - 0102, Toulouse

44000

Local Institution - 0085, Nantes

47014

Local Institution - 0043, Forlì

48109

Local Institution - 0004, Ann Arbor

55131

Local Institution - 0052, Mainz

68130

Local Institution - 0076, Omaha

72076

Local Institution - 0054, Tübingen

72762

Local Institution - 0059, Springdale

73104

Local Institution - 0028, Oklahoma City

75010

Local Institution - 0068, Paris

75246

Local Institution - 0010, Dallas

75702

Local Institution - 0013, Tyler

77030

Local Institution - 0018, Houston

78240

Local Institution - 0006, San Antonio

78705

Local Institution - 0011, Austin

80131

Local Institution - 0027, Napoli

80228

Local Institution - 0007, Lakewood

84112

Local Institution - 0058, Salt Lake City

89169

Comprehensive Cancer Centers Of Nevada, Las Vegas

90033

Local Institution - 0099, Los Angeles

94800

Local Institution - 0069, Villejuif

97401

Local Institution - 0017, Eugene

02215

Local Institution - 0060, Boston

07601

Local Institution - 0005, Hackensack

08903

Local Institution - 0032, New Brunswick

76104-3927

Local Institution - 0014, Fort Worth

VIC 3350

Local Institution - 0091, Ballarat Central

T6G 1Z2

Local Institution - 0030, Edmonton

V5Z 4E6

Local Institution - 0029, Vancouver

V8R 6V5

Local Institution - 0078, Victoria

M5G 1Z5

Local Institution - 0020, Toronto

M5G 2M9

Local Institution - 0055, Toronto

H2X 0A9

Local Institution - 0056, Montreal

31-115

Local Institution - 0071, Krakow

02-781

Local Institution - 0077, Warsaw

221 85

Local Institution - 0049, Lund

M20 4BX

Local Institution - 0024, Manchester

G12 0YN

Local Institution - 0083, Glasgow

B15 2TH

Local Institution - 0019, Birmingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY